The American healthcare system runs on a reimbursement clock most patients never see, and the margins left to providers after billing and compliance costs are shrinking. Castle Rock Hormone Health operates outside that cycle on a direct-pay model and is preparing to open between 100 and 250 clinics in 2026.
When the Insurance Model Stops Making Sense
With hospital operating margins projected at 1.5 to 2 percent in 2026 against medical cost trends near 8.5 percent, more operators are moving toward direct-pay models that eliminate billing overhead and prior authorization staff. The structural simplicity matters most at the franchise level, where predictable revenue per site drives unit economics. Castle Rock Hormone Health’s $350,000 minimum investment reflects that lower infrastructure burden – well below comparable medspa and anti-aging concepts that can require above $800,000.
The Recurring Revenue Argument
The cash-pay business case rests on the returning patient, not the single visit. Hormone optimization requires quarterly labs, dosage adjustments, and ongoing management, and research on wellness memberships shows repeat patients spend 67 percent more than new clients while a 5 percent retention lift can raise profits by 25 percent. Castle Rock’s 90-day lab cycle creates four scheduled touchpoints per patient per year, turning the revenue model into something closer to a subscription business than a traditional clinic.
Why Franchise Investors Are Paying Closer Attention
The global concierge medicine market is projected to grow from $20.40 billion in 2024 to $39 billion by 2034, and Harvard Medical School research found concierge and direct primary care practices grew 83 percent from 2018 to 2023. Castle Rock Hormone Health is, according to the company, the first hormone optimization franchise to serve both men and women at national scale.
“This is no longer a niche category. Patients are actively seeking personalized, ongoing care, and expanding hormone optimization to both men and women reflects where the market is heading,” says Chris Stolzman, CEO and Co-Founder.
With multiple revenue lines per patient across hormone replacement, weight loss, peptides, IV therapy, and sexual wellness, Castle Rock matches the profile the IFA’s 2026 Franchising Economic Outlook flagged as the strongest-performing 2026 category: asset-light franchises with recurring revenue.
